Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
30
KALA Quote, Financials, Valuation and Earnings
Last price:
$0.68
Seasonality move
:
34.27%
Day range:
$0.67 - $0.80
52-week range:
$0.61 - $20.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.18x
P/B ratio:
8.34x
Volume:
2.9M
Avg. volume:
14.3M
1-year change:
-88.81%
Market cap:
$5.7M
Revenue:
--
EPS (TTM):
-$5.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
-- | -$1.10 | -- | -43.13% | $1.50 |
|
AKRO
Akero Therapeutics, Inc.
|
-- | -$0.93 | -- | -0.63% | $56.00 |
|
ALLO
Allogene Therapeutics, Inc.
|
$1.8K | -$0.23 | -92.41% | -21.56% | $7.56 |
|
BLTE
Belite Bio, Inc.
|
-- | -$0.49 | -- | -58.83% | $184.33 |
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | -- | -- | -- | -- |
|
QTTB
Q32 Bio, Inc.
|
-- | -- | -100% | -- | $15.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
$0.69 | $1.50 | $5.7M | -- | $0.00 | 0% | 7.18x |
|
AKRO
Akero Therapeutics, Inc.
|
$54.65 | $56.00 | $4.5B | -- | $0.00 | 0% | -- |
|
ALLO
Allogene Therapeutics, Inc.
|
$1.55 | $7.56 | $348.3M | -- | $0.00 | 0% | 2,442.58x |
|
BLTE
Belite Bio, Inc.
|
$150.24 | $184.33 | $5.6B | -- | $0.00 | 0% | -- |
|
PMCB
PharmaCyte Biotech, Inc.
|
$1.02 | -- | $6.9M | 0.40x | $0.00 | 0% | 239.61x |
|
QTTB
Q32 Bio, Inc.
|
$3.18 | $15.00 | $39.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
140.72% | 1.386 | 263.3% | 0.65x |
|
AKRO
Akero Therapeutics, Inc.
|
0.12% | 3.225 | 0.03% | 15.48x |
|
ALLO
Allogene Therapeutics, Inc.
|
21.26% | -0.074 | 30.77% | 7.92x |
|
BLTE
Belite Bio, Inc.
|
0.19% | -0.369 | 0.02% | 34.17x |
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | 1.242 | -- | 12.67x |
|
QTTB
Q32 Bio, Inc.
|
-1196.42% | 5.520 | 69.88% | 4.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
-$128K | -$10.7M | -102.67% | -1375.54% | -- | -$10.9M |
|
AKRO
Akero Therapeutics, Inc.
|
-- | -$90.2M | -31.13% | -32.14% | -- | -$67.2M |
|
ALLO
Allogene Therapeutics, Inc.
|
-$3.1M | -$44.9M | -44.62% | -54.89% | -315927.27% | -$29.9M |
|
BLTE
Belite Bio, Inc.
|
-$347K | -$23M | -37.09% | -37.13% | -- | -- |
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | -$848.3K | -2.42% | -2.42% | -- | -$2M |
|
QTTB
Q32 Bio, Inc.
|
-$91K | -$7.6M | -256.32% | -634.27% | -- | -$4.2M |
Kala Bio, Inc. vs. Competitors
-
Which has Higher Returns KALA or AKRO?
Akero Therapeutics, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat Akero Therapeutics, Inc.'s return on equity of -32.14%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M AKROAkero Therapeutics, Inc.-- -$0.99 $958.8M -
What do Analysts Say About KALA or AKRO?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 115.89%. On the other hand Akero Therapeutics, Inc. has an analysts' consensus of $56.00 which suggests that it could grow by 2.47%. Given that Kala Bio, Inc. has higher upside potential than Akero Therapeutics, Inc., analysts believe Kala Bio, Inc. is more attractive than Akero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 AKROAkero Therapeutics, Inc.1 4 0 -
Is KALA or AKRO More Risky?
Kala Bio, Inc. has a beta of -2.494, which suggesting that the stock is 349.43% less volatile than S&P 500. In comparison Akero Therapeutics, Inc. has a beta of -0.399, suggesting its less volatile than the S&P 500 by 139.855%.
-
Which is a Better Dividend Stock KALA or AKRO?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Akero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or AKRO?
Kala Bio, Inc. quarterly revenues are --, which are smaller than Akero Therapeutics, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is higher than Akero Therapeutics, Inc.'s net income of -$81.6M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Akero Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus -- for Akero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M AKROAkero Therapeutics, Inc.-- -- -- -$81.6M
-
Which has Higher Returns KALA or ALLO?
Allogene Therapeutics, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of -295454.55%. Kala Bio, Inc.'s return on equity of -1375.54% beat Allogene Therapeutics, Inc.'s return on equity of -54.89%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M -
What do Analysts Say About KALA or ALLO?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 115.89%. On the other hand Allogene Therapeutics, Inc. has an analysts' consensus of $7.56 which suggests that it could grow by 387.74%. Given that Allogene Therapeutics, Inc. has higher upside potential than Kala Bio, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than Kala Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 ALLOAllogene Therapeutics, Inc.9 2 0 -
Is KALA or ALLO More Risky?
Kala Bio, Inc. has a beta of -2.494, which suggesting that the stock is 349.43% less volatile than S&P 500. In comparison Allogene Therapeutics, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.924%.
-
Which is a Better Dividend Stock KALA or ALLO?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Allogene Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or ALLO?
Kala Bio, Inc. quarterly revenues are --, which are smaller than Allogene Therapeutics, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is higher than Allogene Therapeutics, Inc.'s net income of -$41.4M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Allogene Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus 2,442.58x for Allogene Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M
-
Which has Higher Returns KALA or BLTE?
Belite Bio, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat Belite Bio, Inc.'s return on equity of -37.13%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M BLTEBelite Bio, Inc.-- -$0.65 $274.6M -
What do Analysts Say About KALA or BLTE?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 115.89%. On the other hand Belite Bio, Inc. has an analysts' consensus of $184.33 which suggests that it could grow by 22.69%. Given that Kala Bio, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Kala Bio, Inc. is more attractive than Belite Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 BLTEBelite Bio, Inc.5 0 0 -
Is KALA or BLTE More Risky?
Kala Bio, Inc. has a beta of -2.494, which suggesting that the stock is 349.43% less volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KALA or BLTE?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or BLTE?
Kala Bio, Inc. quarterly revenues are --, which are smaller than Belite Bio, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is higher than Belite Bio, Inc.'s net income of -$21.7M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M BLTEBelite Bio, Inc.-- -- -- -$21.7M
-
Which has Higher Returns KALA or PMCB?
PharmaCyte Biotech, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat PharmaCyte Biotech, Inc.'s return on equity of -2.42%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M PMCBPharmaCyte Biotech, Inc.-- -$1.23 $43.6M -
What do Analysts Say About KALA or PMCB?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 115.89%. On the other hand PharmaCyte Biotech, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kala Bio, Inc. has higher upside potential than PharmaCyte Biotech, Inc., analysts believe Kala Bio, Inc. is more attractive than PharmaCyte Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 PMCBPharmaCyte Biotech, Inc.0 0 0 -
Is KALA or PMCB More Risky?
Kala Bio, Inc. has a beta of -2.494, which suggesting that the stock is 349.43% less volatile than S&P 500. In comparison PharmaCyte Biotech, Inc. has a beta of 0.064, suggesting its less volatile than the S&P 500 by 93.571%.
-
Which is a Better Dividend Stock KALA or PMCB?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PharmaCyte Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. PharmaCyte Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or PMCB?
Kala Bio, Inc. quarterly revenues are --, which are smaller than PharmaCyte Biotech, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is higher than PharmaCyte Biotech, Inc.'s net income of -$8.4M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while PharmaCyte Biotech, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus 239.61x for PharmaCyte Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M PMCBPharmaCyte Biotech, Inc.239.61x 0.40x -- -$8.4M
-
Which has Higher Returns KALA or QTTB?
Q32 Bio, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat Q32 Bio, Inc.'s return on equity of -634.27%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M -
What do Analysts Say About KALA or QTTB?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 115.89%. On the other hand Q32 Bio, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 371.7%. Given that Q32 Bio, Inc. has higher upside potential than Kala Bio, Inc., analysts believe Q32 Bio, Inc. is more attractive than Kala Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 QTTBQ32 Bio, Inc.1 1 0 -
Is KALA or QTTB More Risky?
Kala Bio, Inc. has a beta of -2.494, which suggesting that the stock is 349.43% less volatile than S&P 500. In comparison Q32 Bio, Inc. has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.253%.
-
Which is a Better Dividend Stock KALA or QTTB?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Q32 Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Q32 Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or QTTB?
Kala Bio, Inc. quarterly revenues are --, which are smaller than Q32 Bio, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is lower than Q32 Bio, Inc.'s net income of -$7.4M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Q32 Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus -- for Q32 Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M QTTBQ32 Bio, Inc.-- -- -- -$7.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
54
SMX alert for Dec 12
SMX (Security Matters) Plc [SMX] is down 14.67% over the past day.
Buy
77
DHIL alert for Dec 12
Diamond Hill Investment Group, Inc. [DHIL] is down 0.54% over the past day.
Sell
28
OXM alert for Dec 12
Oxford Industries, Inc. [OXM] is up 9.32% over the past day.
